Aberdeen Group plc Acquires New Shares in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Aberdeen Group plc acquired a new stake of 271,574 shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in Q4, worth approximately $13.5 million, representing about 0.47% of the company.
• Company insiders sold a total of 120,881 shares (roughly $6.14M) in the last quarter — including VP Padmanabh Bhatt's sale of 50,000 shares — leaving insiders with 8.8% ownership, indicating notable insider selling.
• Analyst coverage is mixed with a MarketBeat consensus of Hold and an average price target of $62.17 (four Buys, one Hold, two Sells), while individual targets and ratings range from downgrades to $65 price forecasts.

Aberdeen Group plc acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 271,574 shares of the specialty pharmaceutical company's stock, valued at approximately $13,497,000. Aberdeen Group plc owned 0.47% of Supernus Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC acquired a new position in Supernus Pharmaceuticals during the 4th quarter valued at approximately $284,000. Waldron Private Wealth LLC acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $215,000. Wedge Capital Management L L P NC increased its stake in shares of Supernus Pharmaceuticals by 12.2% in the fourth quarter. Wedge Capital Management L L P NC now owns 78,095 shares of the specialty pharmaceutical company's stock valued at $3,881,000 after purchasing an additional 8,514 shares during the period. CoreCap Advisors LLC increased its stake in shares of Supernus Pharmaceuticals by 2,643.7% in the fourth quarter. CoreCap Advisors LLC now owns 8,231 shares of the specialty pharmaceutical company's stock valued at $409,000 after purchasing an additional 7,931 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of Supernus Pharmaceuticals by 23.6% in the fourth quarter. SG Americas Securities LLC now owns 12,800 shares of the specialty pharmaceutical company's stock valued at $636,000 after purchasing an additional 2,447 shares during the period.

Wall Street Analyst Weigh In

SUPN has been the topic of several analyst reports. Stifel Nicolaus raised their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a "hold" rating in a research note on Friday, December 19th. Weiss Ratings restated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Sunday, March 8th. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Finally, Zacks Research downgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a report on Thursday, January 29th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of "Hold" and an average target price of $62.17.

Insider Activity at Supernus Pharmaceuticals

In other news, Director Frederick M. Hudson sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $50.61, for a total transaction of $271,725.09. Following the transaction, the director directly owned 60,413 shares in the company, valued at approximately $3,057,501.93. This trade represents a 8.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction on Monday, March 16th. The shares were sold at an average price of $50.28, for a total value of $2,514,000.00. Following the transaction, the vice president owned 17,044 shares in the company, valued at approximately $856,972.32. This trade represents a 74.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 120,881 shares of company stock worth $6,139,356 in the last quarter. Company insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Stock Up 0.8%

SUPN stock opened at $50.96 on Wednesday. The company has a market capitalization of $2.93 billion, a P/E ratio of -74.94, a PEG ratio of 1.57 and a beta of 0.73. The company has a 50-day simple moving average of $51.19 and a 200 day simple moving average of $49.66. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $59.68.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.